Reading VERA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VERA free→Reading VERA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VERA free→QuarterlyIQ Insights · VERA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On June 2, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy. The eGFR results are now expected in the third quarter of 2026. Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval of ataci…
Results of Operations and Financial Condition On May 7, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for first quarter ended March 31, 2026, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 5, 2026, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christopher Hite to the Board, effective immediately. Mr. Hite will serve as a Class III Director, with an initial term expiring at the Company’s 2027 Annual Meeting of Stockholders. Contingent upon and effective as of Mr. Hite’s appointment…
Results of Operations and Financial Condition On February 26, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deem…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 16, 2025, Vera Therapeutics, Inc. (the “Company”) announced that Jason Carter will no longer serve as the Company’s Chief Legal Officer, effective as of December 24, 2025. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersign…
Other Events. Follow-On Public Offering On December 9, 2025, Vera Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 6,138,108 shares of the Company’s Class A common stock, par va…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 25, 2025, the board of directors (the “ Board ”) of Vera Therapeutics, Inc. (the “ Company ”) appointed James R. Meyers to the Board, effective immediately. Mr. Meyers will serve as a Class II Director, with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders. Mr. Meyers was also appointed to serve on the Audit…
Results of Operations and Financial Condition On November 5, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be…
Entry into a Material Definitive Agreement. On August 5, 2025, Vera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”). Under the Sales Agreement, the Company may offer and sell, from time to time, through TD Cowen as its sales agent and/or principal, shares of its Class A common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering amount of up to $200 million (the “Shares”). The S…
Termination of a Material Definitive Agreement. The information set forth above in
Results of Operations and Financial Condition On August 5, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Entry into a Material Definitive Agreement. On June 2, 2025 (the “Effective Date”), Vera Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”). The Agreement provides for term loans in an aggregate principal amount of up to $500.0 million. Under the terms of the Agreement, the Lender…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Other Events. As noted in Item 7.01, on June 2, 2025, the Company announced positive 36-week data from the Company’s ORIGIN Phase 3 clinical trial of atacicept in adult patients with IgAN. Atacicept is the Company’s potential best-in-class, disease-modifying dual inhibitor of the cytokines B-cell activating factor and a proliferation-inducing ligand. ORIGIN Phase 3 is an ongoing global, multicenter, randomized, double-blind, placebo-controlled clinical trial of 431 adults evaluating the effic…
Results of Operations and Financial Condition On May 6, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Results of Operations and Financial Condition On February 26, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.